SCHEMBL19975243

SCHEMBL19975243

CC(NS(=O)(=O)c1ccccc1Cl)C(O)C(=O)NCC1CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.45
CTSL P07711 2/20 0.44
CTSS P25774 2/20 0.44
CTSK P43235 2/20 0.44
ITGAV P06756 1/20 0.43
ALDH1A1 P00352 2/20 0.42
SLC1A3 P43003 1/20 0.42
SLC1A2 P43004 1/20 0.42
SLC1A1 P43005 1/20 0.42
BMP1 P13497 1/20 0.41
THRB P10828 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.40
TP53 P04637 2/20 0.40
MAPT P10636 2/20 0.40
HSD11B1 P28845 1/20 0.39
CTSB P07858 1/20 0.39
MEN1 O00255 3/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19974832 0.87 ITGAV (0.44) KMT2AITGAVALDH1A1SLC1A3SLC1A2
SCHEMBL19974734 0.84 ITGAV (0.47) KMT2AITGAVALDH1A1L3MBTL1TP53
SCHEMBL19975337 0.83 KMT2A (0.54) KMT2AALDH1A1MEN1NPY5RFBP1
SCHEMBL21176298 0.81 KMT2A (0.52) KMT2AALDH1A1THRBMEN1
SCHEMBL19975110 0.81 KMT2A (0.46) KMT2ACTSLCTSSCTSKITGAV
SCHEMBL19975436 0.78 KMT2A (0.48) KMT2AALDH1A1MEN1NPY5R
SCHEMBL19974744 0.78 KMT2A (0.64) KMT2AALDH1A1L3MBTL1MAPTMEN1
SCHEMBL19975234 0.77 F2 (0.43) KMT2AALDH1A1SLC1A3SLC1A2SLC1A1
SCHEMBL19974908 0.77 KMT2A (0.52) KMT2ACTSLCTSSCTSKALDH1A1
SCHEMBL19974926 0.77 SMN1; SMN2 (0.47) KMT2AALDH1A1RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220356148-A1 ANTIVIRAL COMPOUNDS HAPLOGEN GMBH (AT) 2022-11-10 US disclosed
US-11091428-B2 Antiviral compounds HAPLOGEN GMBH (AT) 2021-08-17 US disclosed
US-11091428-B2 Antiviral compounds HAPLOGEN GMBH (AT) 2021-08-17 US disclosed
CN-110062753-A Antiviral compounds 哈普洛根有限责任公司 2019-07-26 CN disclosed
US-20190225575-A1 ANTIVIRAL COMPOUNDS LUNIS CONSULTING GMBH (AT) 2019-07-25 US disclosed
US-20190225575-A1 ANTIVIRAL COMPOUNDS LUNIS CONSULTING GMBH (AT) 2019-07-25 US disclosed
EP-3512836-A1 ANTIVIRAL COMPOUNDS Haplogen GmbH (AT) 2019-07-24 EP disclosed
WO-2018050631-A1 ANTIVIRAL COMPOUNDS HAPLOGEN GMBH (AT) 2018-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190225575-A1 ANTIVIRAL COMPOUNDS PLA2G1B, PLA2G12A, PLA2G4C KMT2A 4031/4885CTSL 899/4885CTSS 675/4885
US-20220356148-A1 ANTIVIRAL COMPOUNDS PLA2G12A, PLA2G1B, PLA2G4C KMT2A 4177/4885CTSL 958/4885CTSS 821/4885
US-11091428-B2 Antiviral compounds PLA2G1B, PLA2G12A, PLA2G4C KMT2A 4031/4885CTSL 899/4885CTSS 675/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.